Prognostic factors for the outcome of methotrexate treatment in rheumatoid arthritis
- 1 September 1995
- journal article
- research article
- Published by Springer Nature in Clinical Rheumatology
- Vol. 14 (5) , 515-518
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- The effect of methotrexate on soluble interleukin‐2 receptor levels in rheumatoid arthritis: comment on the article by barrera et alArthritis & Rheumatism, 1994
- Interleukin‐2 Receptor Levels in the Sera of Rheumatoid Arthritis Patients Treated with MethotrexateArthritis & Rheumatism, 1994
- Circulating soluble tumor necrosis factor receptors, interleukin‐2 receptors, tumor necrosis factor α, and interleukin‐6 levels in rheumatoid arthritis.Arthritis & Rheumatism, 1993
- Human neutrophil activating peptide/interleukin 8 acts as an autoantigen in rheumatoid arthritis.Annals of the Rheumatic Diseases, 1992
- Presence of NAP‐1/IL‐8 in Synovial Fluids Indicates a Possible Pathogenic Role in Rheumatoid ArthritisScandinavian Journal of Immunology, 1991
- COMPARATIVE CONTROLLED TRIAL OF LOW-DOSE WEEKLY METHOTREXATE VERSUS AZATHIOPRINE IN RHUEMATIOD ARTHRITIS: 3-YEAR PROSPECTIVE STUDYRheumatology, 1990
- PROSPECTIVE LONG TERM FOLLOW-UP OF METHOTREXATE THERAPY IN RHEUMATOID ARTHRITIS: TOXICITY, EFFICACY AND RADIOLOGICAL PROGRESSIONRheumatology, 1989
- Methotrexate in rheumatoid arthritisArthritis & Rheumatism, 1988
- The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritisArthritis & Rheumatism, 1988
- Methotrexat-Behandlung der chronischen PolyarthritisDMW - Deutsche Medizinische Wochenschrift, 1987